Human papillomavirus vaccine and cervical cancer prevention: Practice and policy implications for pharmacists

Journal of the American Pharmacists Association

Volumn 48, Issue 1, 2008, Pages

  McIntosh, Jennifer ^a   Sturpe, Deborah A ^b   Khanna, Niharika ^c  

^a NORTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Community pharmacy; Gynecology; Human papillomavirus vaccine; Immunizations; Pharmacy services; Public health; Women's health

Indexed keywords

HUMAN PAPILLOMAVIRUS VACCINE L1, TYPE 6,11,16,18; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADOLESCENT; ADULT; CHILD; CLINICAL TRIAL; FEMALE; HEALTH CARE POLICY; HUMAN; PHARMACIST; PRECANCER; PROFESSIONAL STANDARD; REVIEW; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ADOLESCENT; ADULT; CHILD; CLINICAL TRIALS AS TOPIC; FEMALE; HEALTH POLICY; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PHARMACISTS; PRECANCEROUS CONDITIONS; PROFESSIONAL ROLE; UTERINE CERVICAL NEOPLASMS;

EID: 38749139524     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA/2008.07032     Document Type: Review

References (90)

1. Centers for Disease Control and Prevention. HPV vaccine questions and answers. Accessed at www.cdc.gov/std/hpv/STDFact-HPV-vaccine.htm, January 25, 2007.
2. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813-9.
3. Winer RL, Hughes JP, Feng Q, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354:2645-54.
4. American Cancer Society. Cancer facts and figures 2007. Atlanta: American Cancer Society; 2007.
5. Food and Drug Administration. FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus. Accessed at www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html, February 15, 2007.
6. Reuters. Glaxo's Cervarix vaccine gets standard FDA review. Accessed at www.reuters.com/article/governmentFilingsNews/idUSL3118310520070531, July 29, 2007.
7. Tiro JA, Meissner HI, Kobrin S, Chollette V. What do women in the U.S. know about human papillomavirus and cervical cancer? Cancer Epidemiol Biomarkers Prev. 2007;16:288-94.
8. Hatz J. HPV vaccine legislation 2007. Accessed at www.ncsl.org/programs/ health/HPVvaccine.htm, February 12, 2007.
9. Texas Executive Order no. RP65: February 2, 2007: relating to the immunization of young women from the cancer-causing Human Papillomavirus. 2007.
10. HB no. 1098: relating to immunization against human papillomavirus: Hegar, trans. 80(R) ed. 2007.
11. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1 : HPV in the etiology of human cancer. Vaccine. 2006;24S3:S1-S10.
12. Gravitt PE, Jamshidi R. Diagnosis and management of oncogenic cervical human papillomavirus infection. Infect Dis Clin North Am. 2005;19:439-58.
13. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-9.
14. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-27.
15. Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol. 1995;33:2058-63.
16. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-65.
17. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132:277-84.
18. Giuliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women's Health Study. J Infect Dis. 2002;186:462-9.
19. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev. 2003;12:485-90.
20. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005;191:182-92.
21. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357:1831-6.
22. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervico-vaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-8.
23. Castellsague X, Munoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis: role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003(31):20-8.
24. Palefsky JM, Holly EA. Chapter 6: immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr. 2003(31):41-6.
25. Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003;361:1159-67.
26. Lehtinen M, Koskela P, Jellum E, et al. Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the Nordic countries. Am J Epidemiol. 2002;156:687-92.
27. Wallin KL, Wiklund F, Luostarinen T, et al. A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer. 2002;101:371-4.
28. Castle PE, Hillier SL, Rabe LK, et al. An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev. 2001;10:1021-7.
29. Yang YC, Chang CL, Huang YW, Wang DY. Possible cofactor in cervical carcinogenesis: proliferation index of the transformation zone in cervicitis. Chang Gung Med J. 2001;24:615-20.
30. Weaver BA, Feng Q, Holmes KK, et al. Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis. 2004;189:677-85.
31. Nicolau SM, Camargo CG, Stavale JN, et al. Human papillomavirus DNA detection in male sexual partners of women with genital human papillomavirus infection. Urology. 2005;65:251-5.
32. Palefsky JM. HPV infection in men. Dis Markers. 2007;23:261-72.
33. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis. 2006;6:21-31.
34. Rombaldi RL, Serafini EP, Villa LL, et al. Infection with human papillomaviruses of sexual partners of women having cervical intraepithelial neoplasia. Braz J Med Biol Res. 2006;39:177-87.
35. Castellsague X, Bosch FX, Munoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med. 2002;346:1105-12.
36. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis. 2005;191(suppl 1):S97-S106.
37. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2006. Accessed at www.cdc.gov/std/treatment/#tg2006, February 16, 2007.
38. American Cancer Society. What is cancer of the cervix? Accessed at www.cancer.org/docroot/CRI/content/CRI-2-2-1X-What-is-cancer-of-the-cervix-8. asp, February 19, 2007.
39. Schmiedeskamp MR, Kockler DR. Human papillomavirus vaccines. Ann Pharmacother. 2006;40:1344-52.
40. Lin YY, Alphs H, Hung CF, et al. Vaccines against human papillomavirus. Front Biosci. 2007;12:246-64.
41. Stanley M, Lowy DR, Frazer I. Chapter 12: prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006;24(suppl 3):S106-S113.
42. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-65.
43. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-8.
44. Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today. 2003;8:934-43.
45. Bryan JT. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine. 2007;25:3001-6.
46. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-27.
47. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-43.
48. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-66.
49. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161-70.
50. Merck Pregnancy Registries: Gardasil. Accessed at www.merck- pregnancyregistries.com/gardasil.html, July 15, 2007.
51. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25:4931-9.
52. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118:2135-45.
53. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564-71.
54. NIH Clinical Trials Registry. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of Gardasil (V501) given concomitantly with Repevax in healthy adolescents 11-17 years of age. Accessed at www.clinicaltrials.gov/ct/show/NCT00337428?order=1, February 8, 2007.
55. NIH Clinical Trials Registry. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of Gardasil (V501) given concomitantly with Menactra and Adacel in healthy adolescents 11-17 years of age. Accessed at www.clinicaltrials.gov/ct/show/NCT00325130?order=1, February 8, 2007.
56. Harro CD, Pang YY, Roden RB, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001;93:284-92.
57. NIH Clinical Trials Registry. An investigational vaccine in reducing the incidence of anogenital warts in young men. Accessed at www.clinicaltrials.gov/ ct/show/NCT00090285?order=1, February 8, 2007.
58. Schwarz TF. An AS04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15-55 years old [abstract]. J Clin Oncol. 2006;24(18 suppl):1008.
59. NIH Clinical Trials Registry. A study to evaluate the safety, immunogenicity, and efficacy of GSK biologicals HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above. Accessed at www.clinicaltrials.gov/ct/show/NCT00294047?order=1, February 5, 2007.
60. NIH Clinical Trials Registry. Safety, immunogenicity, and efficacy of Gardasil (V501) (human papilloma virus [types 6, 11, 16, 18] recombinant vaccine) in mid-adult women: the FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) study. Accessed at www.clinicaltrials.gov/ct/ show/NCT00090220?order=1, February 5, 2007.
61. Kruger Kjær S, Tryggvadottir L, Dillner J, et al. Long term safety and effectiveness follow-up of Gardasil recipients in the Nordic region Paper presented at: 23rd International Papillomavirus Conference & Clinical Workshop; September 1-7, 2006; Prague, Czech Republic.
62. Lehtinen M, Apter D, Dubin G, et al. Enrollment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS. 2006;17:517-21.
63. Lehtinen M, Idanpaan-Heikkila I, Lunnas T, et al. Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy. Int J STD AIDS. 2006;17:237-46.
64. Bratti MC, Rodriguez AC, Schiffman M, et al. Description of a 7-year prospective study of human papillomavirus infection and cervical neoplasia among 10,000 women in Guanacaste, Costa Rica. Rev Panam Salud Publica. 2004;15:75-89.
65. NIH Clinical Trials Registry. A double-blind, controlled, randomized Phase III study of the efficacy of an HPV16/18 VLP vaccine in the prevention of advanced cervical intraepithelial neoplasia (CIN2, CIN3, adenocarcinoma in situ [AIS] and invasive cervical cancer) associated with HPV 16 or HPV 18 cervical infection in healthy young adult women in Costa Rica. Accessed at www.clinicaltrials.gov/ct/show/NCT00128661?order=1, February 8, 2007.
66. Gambhira R, Buck C, Bossis I, et al. Cross protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N-terminus of HPV 16 minor capsid antigen L2. Paper presented at: 23rd International Papillomavirus Conference & Clinical Workshop; September 1-7, 2006; Prague, Czech Republic.
67. Yang R, Wheeler CM, Chen X, et al. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J Virol. 2005;79:6741-50.
68. Bianchi M, Baud D, Bobst M, Haefliger DN. Vaginal immunization of mice with recombinant HPV16-salmonella as a potential route of vaccination against cervical cancer. Paper presented at: 23rd International Papillomavirus Conference & Clinical Workshop; September 1-7, 2006; Prague, Czech Republic.
69. Thoenes N, Mueller M. Oral immunogenicity of different HPV 16 L1 assembly forms. Paper presented at: 23rd International Papillomavirus Conference & Clinical Workshop; September 1-7, 2006; Prague, Czech Republic.
70. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. Accessed at www.cdc.gov/nip/acip/, February 17, 2007.
71. Institute of Medicine. Calling the shots: immunization finance policies and practices. Washington, D.C.: National Academy Press; 2000.
72. Committee on Infectious Diseases. Recommended immunization schedules for children and adolescents: United States, 2007. Pediatrics. 2007;119:207-8.
73. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56:1-24.
74. Schiller JT, Lowy DR. Prospects for cervical cancer prevention by human papillomavirus vaccination. Cancer Res. 2006;66:10229-32.
75. Association AM. Guidelines for Adolescent Preventive Services (GAPS). Recommendations monograph. Chicago: American Medical Association; 1994.
76. Green M, Palfrey JS, eds. Bright futures: guidelines for health supervisions for infants, children and adolescents. 2nd ed. Arlington, Va.: National Center for Education in Maternal and Child Health; 2000.
77. Stergachis A, Lander RD, Webb LE. Promoting the pharmacist's role in public health. J Am Pharm Assoc. 2006;46:311-8.
78. Kriescher M. States authorizing immunizations by pharmacists. August 22, 2006. Accessed at www.ncsl.org/programs/health/ImmPhar.htm, January 20, 2007.
79. Hogue MD, Grabenstein JD, Foster SL, Rothholz MC. Pharmacist involvement with immunizations: a decade of professional advancement. J Am Pharm Assoc. 2006;46:168-82.
80. Goad JA. Collaborative practice for pharmacy-based immunization. Pharm Today. 2007(Oct);13(10):77-91.
81. Administrative Rules of Montana 24.174.503 (through Sept 30, 2006). Vol 24.174.503.
82. Md. Health Occupations Code Ann § 12-508(2006).
83. Rupp R, Rosenthal SL, Middleman AB. Vaccination: an opportunity to enhance early adolescent preventative services. J Adolesc Health. 2006;39:461-4.
84. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78-93.
85. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94:334-57.
86. Parham GP, Hicks ML. Racial disparities affecting the reproductive health of African-American women. Med Clin North Am. 2005;89:935-43.
87. Saslow D, Castle PE, Cox JT, et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57:7-28.
88. Task Force on Community Preventive Services. The guide to community preventive services: what works to promote health? New York: Oxford University Press; 2005.
89. Health Resources and Services Administration: Shortage designation. Accessed at http://bhpr.hrsa.gov/shortage/, March 1, 2007.
90. Health Resources and Service Administration. Health Professionals Shortage Areas. Accessed at http://hpsafind.hrsa.gov/, July 31, 2007.